The role of oedema protective drugs in the treatment of chronic venous insufficiency: A review of evidence based on placebo-controlled clinical trials with regard to efficacy and tolerance

Phlebology

Volumn 11, Issue 1, 1996, Pages 23-29

  Diehm, C ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Acad Teach Hosp Univ Heidelberg   (Germany)

Author keywords

Chronic venous insufficiency; Drug therapy; Haemodynamics; Microcirculation; Oedema; Oedema protective agents; Venous ulcer

Indexed keywords

AESCULUS HIPPOCASTANUM EXTRACT; DIOSMIN; MONOXERUTIN; PROTECTIVE AGENT;

ARTICLE; CHRONIC VEIN INSUFFICIENCY; CLINICAL TRIAL; COMPRESSION THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GOOD CLINICAL PRACTICE; HEMODYNAMICS; HUMAN; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ULCER; ULCER HEALING;

EID: 0030036581     PISSN: 02683555     EISSN: None     Source Type: Journal    
DOI: 10.1177/026835559601100106     Document Type: Article

References (62)

1. Kleinsorge H. Stellenwert von Ödemprotektiva zur systemischen Behandlung der venösen Insuffizienz. Vasomed 93;5:267.
2. Berufsverband der praktizierenden Phlebologen. Statement zur Anwendung von Ödemprotektiva. Ärzte Zeitung 93:164.
3. Friedrich HC, Vogelsang H, Neiss A. Ein Beittrag zur Bewertung von intern wirksamen Venenpharmaka. Z Hautkr 1978;11:368.
4. Neiss A, Böhm C. Zum Wirksamkeitsnachweis von Roßkastaniensamenextrakt beim varikösen Symptomenkomplex. MMW 1976;118:213-6.
5. Steiner M. Medikamentöse Therapie der Schwangerschaftsvarikosis mit den O-(β-Hydroxyethly)-rutosiden - eine Therapiestudie, Betahydroxyethylrutoside. Medicon-Verlag, 1990.
6. Steiner M, Hillemann HG. Venostasin retard in the management of venous problems during pregnancy. Phlebology 1990;5:41-4.
7. Quigley FG, Faris IB. A study on the effect of hydroxyethylrutoside on transcutaneous oxygen tension measurements in patients with severe venous insufficiency. Vase Surg 1991;25:42-47.
8. Guillot B, Guilhou JJ, Champvallins de M, Mallet C, Mocatti, Pointel JP. A long term treatment with a venotropic drug. Angiol 1988;8:67-71.
9. MacLennan W, Wilson J, Rattenhuber V, Dikland WJ, Vanderdonck Y, Morian M. Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability. Gerontology 1994;40:45-52.
10. Boccalon H. Methods of evaluation of a drug in phlebology in man. Phlebology 1992;suppl 3:11-12.
11. Diebschlag W, Nocker W, Lehmacher W, Rehn D. A clinical comparison of two doses of O-(β-Hydroxyethly)-rutosides (oxerutins) in patients with chronic venous insufficiency. J Pharm Med 1994;4:7-14.
12. Struckmann J. A review of some non-invasive, volumetric diagnostic techniques in patients with CVI. Phlebology 1990; suppl 1:9-12.
13. Marshall M, Loew D. Diagnostische Maßnahmen zum Nachweis der Wirksamkeit von Venenpharmaka. Phlebology 1994;23:85-91.
14. Barnes MD, Barret DF, White JE. How to measure changes in oedema in patients with chronic venous ulcer. Phlebology 1992;7:31-5.
15. Fischbach JU, Mönter B, Göltner E. Messungen von Armödemen durch optoelektronische Volumetrie. Phlebol u Proktol 1986;15:184-9.
16. Hebeda CL, De Boer EM, Verburgh CA, Krigler RMA, Nieboer C, Bezemer PD. Lower limb volume measurements: standardization and reproducibility of an adapted volometer. Unpublished report, 18 September 1992.
17. Wang J-Z, Mezrich RS, Kostis JB. The use of magnetic resonance imaging in the study of edema. Angiology 1991:4358-64.
18. Berquist D, Hallböök T, Linhagen A. Doppelblindprüfung mit O-(β-Hydroxyethyl)-rutoside bei Patienten mit chronisch venöser Insuffizienz. VASA 1981;10:253-60.
19. Bisler H, Pfeifer R, Klücken N, Pauschinger P. Wirkung von Roßkastamensamenextrakt auf die transkapilläre Filtration bei chronischer venöser Insuffizienz. Dtsch Med Wschr 1986; 35:1321-9.
20. Cesarone MR, Laurora G, Ricci A, Belcaro G, Pomante P, Candiani C, et al. Acute effects of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose comparison study). VASA 1992;21:76-80.
21. Pauschinger P, Wörz E, Zwerger E. Die Messung des Filtrationskoeffizienten am menschlichen Unterschenkel und seine pharmakologische Beeinflussung. MedWelt 1981,32:1954-6.
22. Wienert V, Kamps J. Volumetrische und Venenverschluß plethysmographische Untersuchungen am Unterschenkel mit Hilfe der Computerunterstützten Videoplethysmographie. Phlebol u Proktol 1987;16:134-42.
23. Timeus C. Objektivierung der Wirkung der O-(β-Hydroxyethly)-rutoside auf die menschliche Mikrozirkulation. Zürich: Diss. ETH, 1983.
24. Lagrue G, Behar A. Evaluation par scanning a l'albumin marque au technetium 99 des proprietetes pharmacodynamiques de Daflon 500 sur la permeabilité capillaire. Concilia Medica 1989;2:27-35.
25. Laurent R, DeChampvallins M, Moccatti D, Ochsenbein E, Lucas A, Humbert E. Study of capillary permeability using the histamine induced weal effect of Daflon 500 mg. Zürich: Abstract 305, XVI European Conference on Microcirculation, 1990.
26. Balmer A, Limoni C. A double-blind placebo-controlled clinical trial of Venoruton on the symptoms and signs of chronic venous insufficiency. The importance of patient selection. VASA 1980;9:76-82.
27. De Jongste AB, Jonker JJC, Huisman MV, ten Cate JW, Azar AJ. A double blind three center clinical trial on the short-term efficacy of O-(β-Hydroxyethly)-rutoside in patients with post-thrombotic syndrome. Thromb Haemost 1989;62:826-9.
28. Gilly R, Dillion G, Frileux C. Evaluation of a new venoactive micronised flavonoid fraction (S 5682) in symptomatic disturbance of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology 1994;9:67-70.
29. Laurent R, Gilly R, Frileux C. Clinical evaluation of a venotropic drug in man. Int Angiol 1988;7:39-43.
30. Pilz E. Ödeme bei VEnenerkrankung. Medwelt 1990;41:1143-4.
31. Rudofsky G, Neiß A, Otto K, Seibel K. Ödemprotektive Wirkung und klinische Wirksamkeit von Venostasin retard im Doppelblindversuch. Phelbol. und Proktol. 1986;6:3-20.
32. Serralde FC, Aceves QA. A controlled clinical trial of O-(β-Hydroxyethly)-rutoside in patients with chronic venous insufficiency. Med J Gen Hosp Mexico City 1990;53:102-6.
33. 2 measurements, leg volumetry and ambulatory venous pressure measurements. VASA 1989;18:146-51.
34. Diehm C, Vollbrecht D, Amendt K, Comberg HU. Medical edema protection. Clinical benefit in patients with deep vein incompetence. VASA 1992;21:188-92.
35. Lohr E, Garania P, Jesan P, Fischer H. Ödempräventive Therapie bei chronikscher Veneninsuffizienz mit Ödemneigung. MMW 1986;34:579-81.
36. Nocker W, Diebschlag W, Lehmacher W. Three month, randomised, double blind, dose-response study with O-(β-Hydroxyethly)-rutosides drinking solution. VASA 1989;3:235-8.
37. Diebschlag W. Investigation of the bioequivalence of different galenical preparations of O-(β-Hydroxyethly)-rutosides (HR), Venoruton, following multiple dose peroral administration. Study No. 3064/2530. Internal report 30 October 1992:21-41.
38. Wienert V. Evaluierung eines Wasserplethysmometers. Internal report 1994.
39. Diehm C, Trampisch HJ, Lange S, Schmidt C. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet 1996;347:292-4.
40. Großmann K. Investigation of the additional efficay of oxerutins compared to placebo in CVI patients treated with elastic stockings. Internal report. Munich:Zyma, 1995 (in preparation).
41. Marshall M. Medikamentöse Therapie von chronischen Venenleiden. TW Dermatologie 1993;23:248.
42. Alter H. Zur medikamentösen Therapie der Varikosis. Allgemeinmedizin 1973;27:1301-8.
43. Pulvertaft TB. Paroven in the treatment of chronic venous insufficiency. Practitioner 1979;223:835-41.
44. Bagliani A, Argenteri A, Paravinvi R. Die Verwendung von O-(β-Hydroxyethly)-rutoside in einer neuen galenischen Retardform zur Behandlung der chronisch-venösen Insuffizienz der unteren Extremitäten. G Ital Richerche Clin Ther 1980;12:1-8.
45. Pulvertaft TB. General practice treatment of symptoms of venous insufficiency with oxerutins. Results of a 660 patient multicentre study in the UK. VASA 1983;12:373-6.
46. Chassignolle JF, Amiel M, Lanfranchi G, Barbe R. Activite therapeutique de Daflon 500 mg dans l'insuffisance veineuse fonctionelle. JIM/99 1988:32-35.
47. Van Cauwenberge H. Double blind study of the efficacy of O-(β-Hydroxyethly)-rutosides in the treatment of venous conditions (translated from French). Med Hyg 1978;364:4175-7.
48. McEnroe CS, O'Donnell Jr TF, Mackey WC. Correlation of clinical findings with venous hemodynamics in 386 patients with chronic venous insufficiency. Am J Surg 1988;146:148-52.
49. Barbe R, Amiel M. Pharmacodynamic properties and therapeutic efficacy of Daflon 500 mg. Phlebology 1992;suppl 2:41-4.
50. Marullaz PD, Amiel M, Barbe R. Evaluation of the clinical pharmacological activity of a phlebotonic agent. Int Angiol 1988;7:25-32.
51. Tsouderos Y. Venous tone: are the plebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg. Z Kardiol 1991;80 (suppl 7):95-101.
52. Tsouderos Y. Efficacy of Daflon 500 mg in the treatment of chronic venous insufficiency. Phlebology 1992;supl 2:45-9.
53. Neumann HAM, van den Broek MJTB. Evaluation of O-(β-Hydroxyethly)-rutosides in chronic venous insufficiency by means of non-invasive techniques. Phlebology 1990;5:13-20.
54. Neumann HAM, Van Leeuwen M, Van den Broek MJTB, Berretty PJM. Transcutaneous oxygen tension in chronic venous insufficiency syndrome. VASA 1984;13:213-9.
55. Belcaro G. Letter to the editor. Phlebology 1986;3:189-90.
56. Guilhou JJ, Buillot B, de Champvallins M. Skin systolic pressure in lower limb ulcer: results with Daflon 500 mg. Phlebology 1992;suppl 2:50-2.
57. Alexander House Group. Consensus paper on venous ulcer. Phlebology 1992;21:259-66.
58. Stegmann WAE, Huebner K, Deichmann B, Mueller B. Efficacy of O-(β-Hydroxyethly)-rutosides in the treatment of venous varicose ulcer. Therapiewoche 1986;36:1828-33.
59. Schultz-Ehrenburg U, Müller B. Two multicentre trials of two different dosages (extended abstract). Phlebology 1993;suppl 1:29-30.
60. Zucarelli et al. Treatment with Daflon 500 in patients with venous ulcer. Internal report. Paris:Servier, 1995.
61. Bergstein NAM. Clinical study on the efficacy of O-(β-Hydroxyethly)-rutoside (HR) in varicosis of pregnancy. J Int Med Res 1975;3:189-93.
62. Steiner M. Untersuchungen zur odemvermindernden und ödemprotektiven Wirkung von Roßkastaniensamenextrakt. Phlebol und Proktol 1986:3-8.